ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0845

Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
Abstract Number: 1515

Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Abstract Number: 0423

Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort
Abstract Number: 1765

Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Abstract Number: 0885

MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Abstract Number: 1680

Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Abstract Number: 0706

Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study
Abstract Number: 2264

Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011
Abstract Number: 2045

Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
Abstract Number: 0227

Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
Abstract Number: 1650

Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Abstract Number: 2031

Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
Abstract Number: 2548

Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit
Abstract Number: 1788

Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Abstract Number: 1424

Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].